Vogt Frederick G, Interim CEO and General Counsel of Iovance Biotherapeutics ($IOVA), made one open market purchase of company shares in the last year, totaling $42,250. His most recent buy occurred on May 14, 2025. This purchase ranks 3,194th among nearly 5,000 insiders in our database, where the average buy amounts to about 1.5 million dollars across 3.3 transactions. Vogt has reported no open market sales in the past year.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | A | Restricted Stock Units | 235000 | $0.00 | 235,000.0000 | 357,345 | 9999.99% | 65.76% |
| March 5, 2026 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 62493 | $0.00 | 125,007.0000 | 357,345 | 33.33% | 17.49% |
| March 5, 2026 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 62493 | $0.00 | 556,293.0000 | 357,345 | 12.66% | 17.49% |
| March 5, 2026 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 26755 | $4.58 | 529,538.0000 | 357,345 | 4.81% | 7.49% |
| March 2, 2026 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 10418 | $0.00 | 0.0000 | 357,345 | 100.00% | 2.92% |
| March 2, 2026 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 52087 | $0.00 | 516,609.0000 | 357,345 | 11.21% | 14.58% |
| March 2, 2026 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 22809 | $3.79 | 493,800.0000 | 357,345 | 4.42% | 6.38% |
| March 2, 2026 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 41669 | $0.00 | 166,675.0000 | 357,345 | 20.00% | 11.66% |
| Dec. 1, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 41669 | $0.00 | 476,232.0000 | 334,511 | 9.59% | 12.46% |
| Dec. 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 10417 | $0.00 | 10,418.0000 | 334,511 | 50.00% | 3.11% |
| Dec. 1, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 41669 | $0.00 | 208,344.0000 | 334,511 | 16.67% | 12.46% |
| Dec. 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 4426 | $2.14 | 464,522.0000 | 334,511 | 0.94% | 1.32% |
| Dec. 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 10417 | $0.00 | 468,948.0000 | 334,511 | 2.27% | 3.11% |
| Dec. 1, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 17701 | $2.23 | 458,531.0000 | 334,511 | 3.72% | 5.29% |
| Sept. 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 41669 | $0.00 | 250,013.0000 | 334,511 | 14.29% | 12.46% |
| Sept. 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 52086 | $0.00 | 456,690.0000 | 334,511 | 12.87% | 15.57% |
| Sept. 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 22127 | $2.19 | 434,563.0000 | 334,511 | 4.85% | 6.61% |
| Sept. 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 10417 | $0.00 | 20,385.0000 | 334,511 | 33.82% | 3.11% |
| June 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 10417 | $0.00 | 31,252.0000 | 322,868 | 25.00% | 3.23% |
| June 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 52085 | $0.00 | 426,731.0000 | 322,868 | 13.90% | 16.13% |
| June 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 41668 | $0.00 | 291,682.0000 | 322,868 | 12.50% | 12.91% |
| June 2, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 22127 | $1.76 | 404,604.0000 | 322,868 | 5.19% | 6.85% |
| May 14, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | P | Common Stock | 25000 | $1.69 | 374,646.0000 | 322,868 | 7.15% | 7.74% |
| March 5, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | A | Restricted Stock Units | 187500 | $0.00 | 187,500.0000 | 289,877 | 9999.99% | 64.68% |
| March 3, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 213525 | $0.00 | 333,350.0000 | 289,877 | 39.04% | 73.66% |
| March 3, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 223943 | $0.00 | 445,059.0000 | 289,877 | 101.28% | 77.25% |
| March 3, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 95413 | $4.04 | 349,646.0000 | 289,877 | 21.44% | 32.92% |
| March 3, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 10418 | $0.00 | 41,669.0000 | 289,877 | 20.00% | 3.59% |
| Jan. 14, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 20835 | $0.00 | 0.0000 | 289,877 | 100.00% | 7.19% |
| Jan. 14, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 9955 | $5.89 | 221,116.0000 | 289,877 | 4.31% | 3.43% |
| Jan. 14, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 20835 | $0.00 | 231,071.0000 | 289,877 | 9.91% | 7.19% |
| Dec. 2, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 10417 | $0.00 | 214,662.0000 | 303,269 | 5.10% | 3.43% |
| Dec. 2, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 4426 | $9.07 | 210,236.0000 | 303,269 | 2.06% | 1.46% |
| Dec. 2, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 10417 | $0.00 | 52,087.0000 | 303,269 | 16.67% | 3.43% |
| Oct. 14, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 20834 | $0.00 | 213,096.0000 | 303,269 | 10.84% | 6.87% |
| Oct. 14, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 8851 | $9.77 | 204,245.0000 | 303,269 | 4.15% | 2.92% |
| Oct. 14, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 20834 | $0.00 | 20,835.0000 | 303,269 | 50.00% | 6.87% |
| Sept. 3, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 4426 | $10.85 | 165,300.0000 | 284,817 | 2.61% | 1.55% |
| Sept. 3, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 19913 | $10.85 | 192,262.0000 | 284,817 | 9.39% | 6.99% |
| Sept. 3, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 10417 | $0.00 | 62,504.0000 | 284,817 | 14.29% | 3.66% |
| Sept. 3, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 46875 | $0.00 | 46,875.0000 | 284,817 | 50.00% | 16.46% |
| Sept. 3, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 10417 | $0.00 | 169,726.0000 | 284,817 | 6.54% | 3.66% |
| Sept. 3, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 46875 | $0.00 | 212,175.0000 | 284,817 | 28.36% | 16.46% |
| July 15, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 8851 | $8.68 | 159,309.0000 | 284,817 | 5.26% | 3.11% |
| July 15, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 20835 | $0.00 | 168,160.0000 | 284,817 | 14.14% | 7.32% |
| July 15, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 20835 | $0.00 | 41,669.0000 | 284,817 | 33.33% | 7.32% |
| June 3, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 4426 | $8.37 | 147,325.0000 | 266,220 | 2.92% | 1.66% |
| June 3, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 10417 | $0.00 | 151,751.0000 | 266,220 | 7.37% | 3.91% |
| June 3, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 10417 | $0.00 | 72,921.0000 | 266,220 | 12.50% | 3.91% |
| April 15, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 20834 | $0.00 | 62,504.0000 | 266,220 | 25.00% | 7.83% |
| April 15, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 20834 | $0.00 | 150,185.0000 | 266,220 | 16.11% | 7.83% |
| April 15, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 8851 | $11.89 | 141,334.0000 | 266,220 | 5.89% | 3.32% |
| March 4, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 41662 | $0.00 | 140,800.0000 | 235,131 | 42.02% | 17.72% |
| March 4, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 11449 | $16.96 | 129,351.0000 | 235,131 | 8.13% | 4.87% |
| March 4, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 41662 | $0.00 | 83,338.0000 | 235,131 | 33.33% | 17.72% |
| March 1, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | A | Restricted Stock Units | 93750 | $0.00 | 93,750.0000 | 235,131 | 9999.99% | 39.87% |
| March 1, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | A | Restricted Stock Units | 500000 | $0.00 | 500,000.0000 | 235,131 | 9999.99% | 100.00% |
| Jan. 16, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 6530 | $8.37 | 99,138.0000 | 235,131 | 6.18% | 2.78% |
| Jan. 16, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 20834 | $0.00 | 105,668.0000 | 235,131 | 24.56% | 8.86% |
| Jan. 16, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 20834 | $0.00 | 83,338.0000 | 235,131 | 20.00% | 8.86% |
| Oct. 16, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 20835 | $0.00 | 104,172.0000 | 245,817 | 16.67% | 8.48% |
| Oct. 16, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 8851 | $3.57 | 84,834.0000 | 245,817 | 9.45% | 3.60% |
| Oct. 16, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 20835 | $0.00 | 93,685.0000 | 245,817 | 28.60% | 8.48% |
| July 14, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 20834 | $0.00 | 125,007.0000 | 224,481 | 14.29% | 9.28% |
| July 14, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 20834 | $0.00 | 81,701.0000 | 224,481 | 34.23% | 9.28% |
| July 14, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 8851 | $7.76 | 72,850.0000 | 224,481 | 10.83% | 3.94% |
| April 14, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 20834 | $0.00 | 69,718.0000 | 213,694,000 | 42.62% | 0.01% |
| April 14, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 20834 | $0.00 | 145,841.0000 | 213,694,000 | 12.50% | 0.01% |
| April 14, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 8851 | $5.64 | 60,867.0000 | 213,694,000 | 12.70% | 0.00% |
| March 2, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | See Remarks | A | Stock Option (right to buy) | 500000 | $0.00 | 500,000.0000 | 159,259 | 9999.99% | 100.00% |
| March 2, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | See Remarks | A | Restricted Stock Units | 125000 | $0.00 | 125,000.0000 | 159,259 | 9999.99% | 78.49% |
| Jan. 17, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Common Stock | 83325 | $0.00 | 85,325.0000 | 159,259 | 4166.25% | 52.32% |
| Jan. 17, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | F | Common Stock | 36441 | $6.43 | 48,884.0000 | 159,259 | 42.71% | 22.88% |
| Jan. 17, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Vogt Frederick G | Interim CEO & General Counsel | M | Restricted Stock Units | 83325 | $0.00 | 166,675.0000 | 159,259 | 33.33% | 52.32% |